More on Subhash Dhawab:
Experience
BIOMEDICAL SCIENTIST (INDEPENDENT) Graphic
Senior FDA Research & Regulatory Scientist (Retired)
BIOMEDICAL SCIENTIST (INDEPENDENT)
Jan 2019 - Present4 years 2 months
United States
• Independent science writer
• Invited reviewer of manuscripts for peer-reviewed scientific journals
• Can provide guidance on research and regulatory projects related to in vitro diagnostics, vaccines, and therapeutics
• Can provide short-term or long-term contractual and consulting services for advancing research and regulatory projects
• Can provide editorial assistance
Published six articles and filed a patent application (U.S. and PCT Patent Pending) after retiring from the US FDA in December 2018
FDA Graphic
Senior FDA Research & Regulatory Scientist
FDA
Apr 1993 - Dec 201825 years 9 months
United States
Senior Investigator and Chief, Viral Immunology Section, Laboratory of Molecular Virology
Laboratory Research:
• Directed a comprehensive research program to conduct investigation on HIV-1 and other viruses, including Ebola, Zika, and poxvirus. Other administrative responsibilities included planning, coordinating research with outside collaborators, management, and supervision of research fellows and students.
Product Regulation:
• Provided guidance and…
Department of Cellular Immunology, Walter Reed Army Institute of Research, Washington, D.C. Graphic
Senior National Research Council Associate
Department of Cellular Immunology, Walter Reed Army Institute of Research, Washington, D.C.
Apr 1991 - Mar 19932 years
United States
Investigated HIV-1 pathogenesis regarding how HIV infection is localized to the peripheral and central nervous systems. The major outcome of this highly productive research program revealing marked invasiveness by HIV-infected macrophages defined a previously unknown mechanism for facilitating their escape from the vascular system. These studies yielded a novel experimental modality for designing therapeutic strategies to retard the progression of HIV infection.
Departments of Biochemistry and Pharmacology, Georgetown University Medical Center, Washington, D.C. Graphic
Research Associate (1984-1986)/Research Assistant Professor (1990-1991)
Departments of Biochemistry and Pharmacology, Georgetown University Medical Center, Washington, D.C.
1984 - 19917 years
United States
Work focused on understanding the biochemical and pharmacologic aspects of the neuronal nicotinic receptors which influence the function of nearly all peripheral organs. The major outcome of this work revealed varying distribution of high affinity nicotinic receptors, indicative of the differential sensory functions in the central nervous system, and provided valuable insights into the regulation of nicotinic receptors and in developing new therapeutic modalities for treating neurological…
National Institute of Dental Research, National Institutes of Health, Bethesda, MD Graphic
Senior Staff Fellow
National Institute of Dental Research, National Institutes of Health, Bethesda, MD
Apr 1987 - Apr 19903 years 1 month
United States
Developed a method to identify HTLV-I-binding cell types in heterogeneous leukocyte populations. This work discovered B cells, in addition to T cells, as a new target for HTLV-I infection and provided future directions for evaluating HTLV-I pathogenesis.
Department of Physiology, Duke University Medical Center, Durham, NC Graphic
Research Associate
Department of Physiology, Duke University Medical Center, Durham, NC
Jun 1982 - Dec 19831 year 7 months
United States
Studies focused on the assembly of the low-density lipoprotein (LDL) with particular emphasis on its differential capacity to bind various lipids. These studies provided useful insights into the understanding of the mechanism for apo-LDL interaction with its two major lipid counterparts -- cholesterol and phospholipid -- in defining its role in hyperlipidemic-related cardiovascular disorders.
Education
Central Drug Research Institute, Lucknow, India Graphic
Central Drug Research Institute, Lucknow, India
Ph.D.Biomedical research
1977 - 1981
Publications
Dhawan, S. Is COVID-19 mRNA Vaccination Safe in HIV-1 and Other Retroviral Infections? Am. Pharma. Rev. (Published on December 22, 2022)
American Pharmaceutical Review December 22, 2022
ABSTRACT: Translocation from the cytoplasm to nucleus and integration of reverse-transcribed SARS-CoV-2 spike mRNA into the genomic DNA of COVID-19 mRNA-vaccinated individuals positive for HIV-1 or other retroviral infections HIV-1 or other retroviral infections raise a possibility of generation of a new type of retrovirus. Such retrovirus expressing both HIV-1 receptor-binding domain (gp120) and SARS-CoV-2 receptor-binding domain (SARS-CoV-2-spike protein) could not only have the potential to bind and infect HIV-1 receptor CD4-positive cells but also to CD4-negative-SARS-CoV-2 receptor ACE2-positive cells that are widely distributed in the peripheral vascular and the central nervous system. This perspective raises concerns about these realistic possibilities that need to be scientifically addressed and evaluated in COVID-19 mRNA vaccine recipients infected with retroviruses, including those who are at high risk of acquiring new retroviral infections.
See publicationExternal link
Dhawan, S. Therapeutic potential of inducible endogenous cytoprotective heme oxygenase-1 in mitigating SARS-CoV-2 infection and associated inflammation. Antioxidants 2022, 11: 662.
MDPI March 30, 2022
ABSTRACT: The inducible cytoprotective enzyme heme oxygenase-1 (HO-1) has gained significant recognition in recent years for mediating strong cellular resistance to a broad range of viral infections, regardless of the type of viruses, viral strains, or mutants. HO-1 is not a typical antiviral agent that targets any particular pathogen. It is a “viral tropism independent” endogenous host defense factor that upon induction provides general cellular protection against pathogens. By virtue of HO-1…
See publicationExternal link
Dhawan, S. Simple and economical multifunctional therapeutic swab device system for treating upper respiratory infections, including SARS-CoV-2, on a mass-scale. Am. Pharma. Rev. 2022, 25: 20-24. [March 2022 issue; U.S. and PCT Patent Pending].
American Pharmaceutical Review March 24, 2022
ABSTRACT: New tools are urgently needed to control the current out-of-control COVID-19 pandemic which can be further complicated by annually emerging influenza infections, especially in the winter months. This article offers a simple and economical Therapeutic Swab Device System comprising multifunctional drugs for their direct application to nasal cavity, oral cavity, nasopharynx and posterior pharynx that are the primary sites of upper respiratory infection, including SARS- CoV-2. This system…
See publicationExternal link
Huang. H. et al. Hemin activation abrogates Mycoplasma hyorhinis replication in chronically infected prostate cancer cells via heme oxygenase-1 induction. FEBS Open Bio. 2021, 11:2727-2739.
Wiley August 10, 2021
ABSTRACT: Mycoplasma hyorhinis (M. hyorhinis) lacks a cell wall and resists multiple antibiotics. We describe here the striking > 90% inhibitory effect of hemin, a natural inducer of the cytoprotective enzyme heme oxygenase-1 (HO-1), on M. hyorhinis replication in chronically infected LNCaP prostate cancer cells. The role of HO-1 in interrupting M. hyorhinis replication was confirmed by HO-1-specific siRNA suppression of hemin-induced HO-1 protein expression, which increased intracellular M.…
See publicationExternal link
Dhawan S. Significance of innate immunity in mitigating SARS-CoV-2 infection. Am. Pharma. Rev. 2021, 24:48-49, 2021.
American Pharmaceutical Review June 18, 2021
ABSTRACT: Continuously surging numbers of global COVID-19 cases caused by rapidly emerging SARS-CoV-2 mutants forming more contagious and deadly viral strains force our scientific capacity to find creative ways to control the pandemic. While current SARS-CoV-2 vaccines are quite effective in reducing the severity of the disease, hospitalization and deaths, none is yet known to provide complete protection from acquiring SARS-CoV-2 infections and to prevent reinfections of the recovered adults or…
See publicationExternal link
Dhawan S. Innate cellular immunity for suppressing viral infections. Curr. Trends Immunol. 2021, 22: 19-21.
Research Trends
ABSTRACT: Innate immunity is our first-line, generic/non-specific host defense mechanism against viral infections, regardless of the type of virus. This component of anti-viral immunology could potentially provide initial protection of host cells against viral infections, but it is generally overlooked as a potential candidate for pharmacological enhancement. Although immunization against individual pathogens provides protection against specific infections and reduces disease severity, the…
See publicationExternal link
Dhawan S. Necessity for the evaluation of stimulated cellular immunity against SARS-CoV-2 infection. Curr. Trends Immunol. 2021, 22: 43-47, 2021
Research Trends
ABSTRACT: Innate immunity is the first-line of non-specific host defense mechanism against pathogens, regardless of the type of strains and mutants. This pivotal component of viral immunology, extremely critical for protecting host cells against infections, has largely been overlooked for SARS-CoV-2 infection. While effective immunization against SARS-CoV-2 reduces the severity of the disease, constantly emerging viral mutants and variant strains continue to pose difficult challenges for…
See publicationExternal link
These are most recent publications
-
Patents
"Therapeutic swabs for treating upper respiratory infections" (U.S. and PCT Patent Pending, 2021). Sole Inventor - Subhash Dhawan
Filed August 31, 202117462070
The present invention offers a Therapeutic Swabs Device System as the first therapeutic approach intended to deliver plurality of antiviral, antimicrobial, cytoprotective, anti-inflammatory, and low- or non-anticoagulant drugs to the nasal and oral cavities, nasopharynx, and posterior pharynx, the primary sites of upper respiratory infections. This invention enables an ideal multiprong therapeutic approach for effective targeting of serious upper respiratory infections in humans and in…
Projects
Independent scientific writer • Provides guidance on research and regulatory projects related to in vitro diagnostics, vaccines, and therapeutics • Provides scientific editorial assistance • Amateur self-taught keyboard player
-
More activity by Subhash
#covid #inflammation #resolution #HeatShockResponse Chronic suppression of the physiological #resolution of #inflammation via heat shock proteins…
#covid #inflammation #resolution #HeatShockResponse Chronic suppression of the physiological #resolution of #inflammation via heat shock proteins…
Liked by Subhash Dhawan
January 23, 2023 REPOSTING MY COMMENTS ON Lori Peterson's VERY IMPORTANT LinkedIn POST TWO OR MORE WEEKS AGO. My apologies Dr. Amesh Adalja, but I…
January 23, 2023 REPOSTING MY COMMENTS ON Lori Peterson's VERY IMPORTANT LinkedIn POST TWO OR MORE WEEKS AGO. My apologies Dr. Amesh Adalja, but I…
Shared by Subhash Dhawan
I have mentioned the AI Frame Problem previously. This is a great demonstration of it. The dad is AI, the kids are just plain old I. I programing…
